课题基金 / 基金详情

Tumour cell reprogramming in pancreatic ductal adenocarcinoma as a means for therapeutic resistance

Tumour cell reprogramming in pancreatic ductal adenocarcinoma as a means for therapeutic resistance
胰腺导管腺癌中的肿瘤细胞重编程作为治疗耐药的手段
批准号：
472481
负责人：
Pin Christopher L
金额：
$7.29万
依托单位：
London Health Sciences Centre Res. Inc. (Ont.)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=472481&lang=en
关键词：
Cancer Associated Fibroblasts Chemotherapy Resistance Epigenetics Pancreatic Cancer Patient-Derived Organoids Single Cell Sequencing Tumour Microenvironment

项目摘要

项目成果

Pin Christopher L的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pancreatic cancer kills ~5,700 Canadians every year with most individuals having an expected survival of <1 year after diagnosis. The main reason for these outcomes are relatively late diagnosis - often the cancer has already metastasized, the inefficient
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the role for ATF3 in recurrent pancreatic injury and PDAC
  • 批准号：
    401224
  • 项目类别：
    Operating Grants
  • 资助金额：
    $55.45万
  • 财政年份：
    2019
  • 负责人：
    Pin Christopher L
  • 依托单位：
    University of Western Ontario
Signaling Networks in Pancreatic Disease
海外基金